Virginia Kaklamani, MD, University of Texas Health Science Center

HER2+ Metastatic Breast Cancer: Unmet Needs and Future Directions in Care

June 19th 2023

Closing out her discussion on HER2+ metastatic breast cancer, expert oncologist Virginia Kaklamani, MD, DSc, highlights ongoing unmet needs future directions in care.

Addressing Resistance to HER2-Targeted Therapy in Metastatic Breast Cancer

June 19th 2023

Comprehensive insight on acquired resistance to HER2-targeted therapy in metastatic breast cancer, and how treatments can be selected and sequenced thereafter.

Role of Brain Metastases and Quality of Life in Treatment Decisionmaking

June 12th 2023

Virginia Kaklamani, MD, DSc, shares her perspective on the roles that brain metastases and quality of life play, respectively, in selecting treatment for HER2+ mBC.

Factors in Selecting Third-Line Therapy for HER2+ Metastatic Breast Cancer

June 12th 2023

Focused discussion on factors that help inform treatment selection for patients with HER2+ metastatic breast cancer in the third-line setting.

Patient Profile: A 68-Year-Old Woman With HER2+ Metastatic Breast Cancer

June 5th 2023

Expert oncologist Virginia Kaklamani, MD, DSc, shares her perspectives on a patient case of HER2+ metastatic breast cancer (mBC) treated with multiple lines of therapy.

Impact of Recent Clinical Data on Treatment for HER2+ MBC

June 30th 2020

CDK4/6 Inhibitors for Triple-Positive Breast Cancer

June 30th 2020

SOPHIA: Margetuximab + Chemotherapy for RR HER2+ MBC

June 30th 2020

DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

June 30th 2020

Treatment Choice for Patient Relapsing With Brain Metastases

June 30th 2020

HER2CLIMB: Brain Metastases Data

June 30th 2020

Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

June 30th 2020

HER2+ Early Stage Breast Cancer With Residual Invasive Disease

June 30th 2020

KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

June 30th 2020

TRAIN-2: Anthracyclines in HER2+ Breast Cancer

June 30th 2020

APHINITY and ExteNET Trials for Early-Stage Breast Cancer

June 30th 2020

HER2+ Early-Stage Breast Cancer

June 30th 2020

Guidelines and Approaches to HER2 Testing for Breast Cancer

June 30th 2020

Dr. Kaklamani on Triple Combination Treatment for Breast and Ovarian Cancer

December 31st 2014

Virginia Kaklamani, MD, a professor of medicine in the Division of Hematology/Oncology at the University of Texas Health Sciences Center at San Antonio, discusses a recent clinical trial that looks at the combination of two chemotherapy drugs, carboplatin and eribulin, along with the PARP inhibitor E7449 for the treatment of breast and ovarian cancer.